We conducted a pilot , randomized , open-label study of 28-day ddI-EC capsules monotherapy-administered in a fasted state ( group 1 , n = 11 ) or with food ( group 2 , n = 10 ) to treatment-nave chronically HIV-1-infected individuals .
